search for


Original Article
Outcome of Hematopoietic Stem Cell Transplantation in Wiskott-Aldrich Syndrome
Clin Pediatr Hematol Oncol 2018;25:149-53.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Bo Kyung Kim, M.D., Kyung Taek Hong, M.D., Hyoung Jin Kang, M.D., Ph.D., Jung Yoon Choi, M.D., Hong Yul An, M.D. and Hee Young Shin, M.D.

Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul, Korea
Correspondence to: Hyoung Jin Kang
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, 101 Daehak-ro, Jongno-gu, Seoul 03722, Korea
Tel: +82-2-2072-3304
Fax: +82-2-743-3455
Received September 16, 2018; Revised September 24, 2018; Accepted October 6, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Wiskott-Aldrich syndrome (WAS) is a very rare disease and patients who do not receive timely treatment suffer from bleeding, infection, and malignancy. Hematopoietic stem cell transplantation (HSCT) has been recognized as an effective treatment, but the standard transplantation protocol has not been established. We report the outcomes of WAS patients who underwent HSCT in our institution.
Methods: We retrospectively studied patients who underwent HSCT at Seoul National University Children’s Hospital from 2005 to 2018. Busulfan-based myeloablative conditioning regimen was used, and an intensive daily therapeutic drug monitoring (TDM) for busulfan dosing was started for effective myeloablation and to reduce toxicity since 2008. We collected and analyzed data regarding symptoms, engraftment, transplantation-related toxicities, and survival.
Results: Six WAS patients who received HSCT were evaluated. The median age of the patients at diagnosis was 5 years (range, 1-11). There were 2 matched unrelated donor bone marrow transplantations, 3 matched unrelated peripheral blood stem cell transplantations (PBSCT), and 1 haploidentical PBSCT. No patient experienced engraftment failure. Three patients developed grades II to IV acute graft-versus-host disease (GVHD). Two patients had veno-occlusive disease (VOD). Two patients died (due to VOD and acute GVHD). The 5-year overall survival was 66.7% with 8 years of median follow-up. Particularly, a patient who underwent haploidentical PBSCT using targeted busulfan isalive with a follow-up duration of 3 years after HSCT.
Conclusion:In conclusion, WAS patients may be cured with HSCT with targeted busulfan-based myeloablative conditioning. But, long-term and multi-center studies are needed.
Keywords: Wiskott-Aldrich syndrome, Hematopoietic stem cell transplantation, Busulfan
  1. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome:a comprehensive review. Ann N Y Acad Sci 2013;1285:26-43.
    Pubmed CrossRef
  2. Ozsahin H, Le Deist F, Benkerrou M, et al. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr 1996;129:238-44.
  3. Hacein-Bey Abina S, Gaspar HB, Blondeau J, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA 2015;313:1550-63.
    Pubmed KoreaMed CrossRef
  4. Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with WiskottAldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011;118:1675-84.
    Pubmed KoreaMed CrossRef
  5. Stepensky P, Krauss A, Goldstein G, et al. Impact of conditioning on outcome of hematopoietic stem cell transplantation for wiskott-Aldrich syndrome. J Pediatr Hematol Oncol 2013;35:e234-8.
    Pubmed CrossRef
  6. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for WiskottAldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001;97:1598-603.
    Pubmed CrossRef
  7. Lee JW, Kang HJ, Lee SH, et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant 2012;18:944-50.
    Pubmed CrossRef
  8. Kim B, Lee JW, Hong KT, et al. Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients. Sci Rep 2017;7:1711.
    Pubmed KoreaMed CrossRef
  9. Hong KT, Kang HJ, Choi JY, et al. Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfanbased myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients. Biol Blood Marrow Transplant 2018.
  10. Lee JW, Kang HJ, Kim S, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant 2015;21:190-5.
    Pubmed CrossRef
  11. Kang HJ, Shin HY, Choi HS, Han KS, Ahn HS. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia. Bone Marrow Transplant 2004;33:471-6.
    Pubmed CrossRef
  12. Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 2016;22:4-10.
    Pubmed KoreaMed CrossRef
  13. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplantat 2015;21:389-401.e1.
    Pubmed KoreaMed CrossRef
  14. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010;115:3231-8.
    Pubmed CrossRef
  15. Kamani NR, Kumar S, Hassebroek A, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies:a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2011;17:1783-9.
    Pubmed KoreaMed CrossRef
  16. Pai SY, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006;38:671-9.
    Pubmed CrossRef
  17. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008;14:1936-49.
  18. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002;8:145-54.
    Pubmed CrossRef
  19. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002;53:386-9.
    Pubmed KoreaMed CrossRef
  20. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002;8:468-76.
    Pubmed CrossRef
  21. Kang HJ, Shin HY, Ko SH, et al. Unrelated bone marrow transplantation with a reduced toxicity myeloablative conditioning regimen in Wiskott-Aldrich syndrome. J Korean Med Sci 2008;23:146-8.
    Pubmed KoreaMed CrossRef
  22. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010;126:602-10.e1-11.
  23. Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant 2015;21:604-11.
    Pubmed CrossRef
  24. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015;126:1033-40.
    Pubmed KoreaMed CrossRef
  25. Ghosh N, Karmali R, Rocha V, et al. Reduced-Intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol 2016;34:3141-9.
    Pubmed KoreaMed CrossRef

October 2018, 25 (2)
Full Text PDF
Send to a friend

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Hyoung Jin Kang 

Funding Information